相关实验视频
Updated: Jun 29, 2025

10:03
A Zebrafish Model of Diabetes Mellitus and Metabolic Memory
Published on: February 28, 2013
25.8K
-葡萄糖转运体-2 抑制剂和主要心血管不良结果:SMART-C协作元分析
Siddharth M Patel1,2, Yu Mi Kang1,3, KyungAh Im1,2
1TIMI Study Group (S.M.P., Y.M.K., K.I., M.S.S., S.D.W.), Brigham and Women's Hospital and Harvard Medical School, Boston, MA.
Circulation
|April 7, 2024
概括
在不同患者群体中,-葡萄糖携带体-2 抑制剂 (SGLT2i) 显著降低了主要心血管不良事件 (MACE). 这种益处主要是由于心血管死亡的减少,特别是心力衰竭和突然心脏死亡.
科学领域:
- 心脏病学
- 肝脏病学
- 代谢疾病研究
背景情况:
- 已知SGLT2i可以改善心力衰竭和病的结果.
- 然而,它们对不同患者群体的重大心血管不良事件 (MACE) 的影响需要进一步澄清.
研究的目的:
- 进行协作试验级的元分析,评估SGLT2抑制剂对MACE及其成分的影响.
- 在不同患者群体中检查这些影响,包括动脉样硬化心血管疾病风险,心力衰竭和慢性病患者.
主要方法:
- 一项11项3期,安慰剂控制的SGLT2抑制剂试验的元分析,涉及78,607名患者.
- 评估结果包括MACE,其各个成分,所有原因的死亡率和死亡亚型.
- 根据已确定的心血管疾病,糖尿病,病阶段和白尿进行了亚组分析.
主要成果:
- 在所有患者群体和小组中,SGLT2 抑制剂可使MACE 降低9% (HR,0. 91).
- 这种降低的主要驱动因素是心血管死亡的减少 (HR,0.86),特别是心力衰竭死亡和突然心脏死亡.
- 在整体人群中没有观察到心肌梗塞 (HR,0. 95) 或中风 (HR,0. 99) 的显著影响.
结论:
- 无论基线临床特征如何,SGLT2抑制剂在广泛的患者中有效降低MACE风险.
- 心血管方面的好处主要与心血管死亡的减少有关,特别是心力衰竭和心脏突然死亡.
- 这些发现支持使用SGLT2抑制剂治疗心血管,和代谢疾病.
相关概念视频
Oral Hypoglycemic Agents: Biguanides and Glitazones
195
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
195
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
174
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
174
Glucose Transporters
22.7K
Glucose transporters facilitate the transport of glucose across the cell membrane. In addition to glucose, some glucose transporters can also aid the movement of other hexoses such as fructose, mannose, and galactose.
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
22.7K
Dipeptidyl Peptidase 4 Inhibitors
182
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
182
Secondary Active Transport
119.6K
One example of how cells use the energy contained in electrochemical gradients is demonstrated by glucose transport into cells. The ion vital to this process is sodium (Na+), which is typically present in higher concentrations extracellularly than in the cytosol. Such a concentration difference is due, in part, to the action of an enzyme “pump” embedded in the cellular membrane that actively expels Na+ from a cell. Importantly, as this pump contributes to the high concentration of...
119.6K
Diabetes Mellitus: Type 2 and Gestational
2.3K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
2.3K

